Compare EARN & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | ANIK |
|---|---|---|
| Founded | 2012 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.1M | 191.4M |
| IPO Year | 2012 | 1996 |
| Metric | EARN | ANIK |
|---|---|---|
| Price | $4.79 | $14.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.38 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 392.7K | 110.1K |
| Earning Date | 06-16-2026 | 04-29-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | $7.69 | $5.98 |
| Revenue Next Year | $19.57 | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.27 | $7.90 |
| 52 Week High | $6.08 | $16.24 |
| Indicator | EARN | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 51.88 |
| Support Level | $4.54 | $13.81 |
| Resistance Level | $5.36 | $15.01 |
| Average True Range (ATR) | 0.09 | 0.89 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 92.11 | 68.87 |
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.